Scolaris Content Display Scolaris Content Display

急性虚血性脳卒中に対するセンキュウ(chuanxiong‐type)製剤

Collapse all Expand all

Abstract

available in

Background

Stroke, 88% of which are ischemic, is a common cause of death and disability all over the world. Chuanxiong has been reported to be beneficial in treating stroke. However, the strength of evidence to support its use is unclear.

Objectives

To assess the safety and efficacy of chuanxiong for acute ischemic stroke.

Search methods

We searched the Cochrane Stroke Group Trials Register (last searched January 2008), the Chinese Stroke Trials Register (last searched December 2007), the trials register of the Cochrane Complementary Medicine Field (last searched December 2007), the Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 4, 2007), MEDLINE (1966 to December 2007), EMBASE (1980 to December 2007), CNKI (1979 to December 2007), AMED (1985 to December 2007) and CBM‐disc (1979 to December 2007). We also handsearched appropriate journals and relevant conference proceedings and searched ongoing trials and research registers.

Selection criteria

All randomised controlled trials comparing the clinical outcomes of chuanxiong with placebo or no treatment in patients with acute ischemic stroke (within 14 days of onset).

Data collection and analysis

Two review authors independently selected trials for inclusion, four review authors interviewed study authors to confirm randomisation, and two review authors assessed trial quality, extracted and analysed data.

Main results

Two trials involving 161 participants were included. Both trials were of low quality. Neither of the trials reported the mortality rate or dependency of the participants and no reliable evidence is available in this review.

Authors' conclusions

In the two poor quality trials published, there is insufficient evidence to suggest any clinical recommendations. Well‐designed and performed high‐quality trials are needed.

PICOs

Population
Intervention
Comparison
Outcome

The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.

See more on using PICO in the Cochrane Handbook.

一般語訳

available in

急性虚血性脳卒中に対するセンキュウ(chuanxiong‐type)製剤

脳卒中は一般的な疾患である。脳血管の閉塞または脳出血により発症する。センキュウは中医薬の1つである。中国では、脳卒中患者の治療に広く使われている。本レビューでは、参加者161名の質の低い2件の試験を組み入れた。センキュウの効果について強いエビデンスは見られなかった。この介入法が害よりも有益か否かを示す確かなエビデンスを得るには、十分にデザインした試験の実施が必要である。